IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

|) Approved Product:) MOZOBIL® (plerixafor) | |
|--|--|
|) | |
| 1996) U.S. F.D.A. Approval Date: | |
| | |
| 2009 | |
|) DOLVAMNE) | |
| , | |
| MPOUNDS WITH) | |
| Υ) | |
| 1996) U.S. F.D.A. Approval Date: | |

Mail Stop Hatch-Waxman PTE

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

NOTIFICATION PURSUANT TO 37 C.F.R. § 1.765(a)

Sir:

Pursuant to 37 C.F.R. § 1.765(a), Genzyme Corporation, owner of record of U.S. Patent No. 5,583,131 ("the '131 patent"), hereby notifies the Commissioner that a reissue application pursuant to 35 U.S.C. § 251 was filed on August 15, 2008 in connection with the '131 patent, assigned Reissue Application No. 12/192,704. Genzyme Corporation filed an Application for Extension of Patent Term under 35 U.S.C. § 156 for the '131 patent on February 6, 2009. Both the reissue application and the patent term extension application are pending.

Reissue Application No. 12/192,704 of U.S. Patent No. 5,583,131 claims pharmaceutical compositions comprising plerixafor, which is the active ingredient in the approved MOZOBIL® product. Claims of Reissue Application No. 12/192,704 that read on the MOZOBIL® product include claims 1. 2. and 37.

PATENT Attorney Docket No. 20006 US

Applicants advise the Patent and Trademark Office that Reissue Application No. 12/192,704 is allowed, and the issue fee for this application was paid on December 22, 2010. Applicants request that the certificate of patent term extension be applied to the granted reissue patent for Reissue Application No. 12/192,704. Applicants will advise the Patent and Trademark Office promptly once the reissued patent is granted.

Respectfully submitted.

Charles E Van Horn Date: December 23, 2010

> Attorney for Applicants Reg. No. 40,266

Customer No. 22852

Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P. 901 New York Avenue, N.W.

Washington, D.C. 20001-4413 Phone: 202-408-4000